Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXN-32 and EXN-44 in Parkinson's disease with motor fluctuations
2017-000262-30Phase 2Completed
- Sponsor
- Dr. Reddy's Laboratories
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of EXN-32 and EXN-44 in Parkinson's disease (PD) (3 arms), sponsored by Dr. Reddy's Laboratories. Primary endpoint: Pharmacodynamic / Efficacy endpoints. Started Nov 2020; status: completed.
02
Drugs
EXN-32EXN-44
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2017-000262-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000262-30.